Takeda - The top 10 largest pharma layoffs in 2013

Company: Takeda
Based: Osaka, Japan
Announced layoffs: 1,500

Newcomer CFO François-Xavier Roger didn't waste any time after taking up the role in September. By November, he had fleshed out the details of Takeda's "Project Summit," a cost-cutting drive it first announced in May. Those details included an up to 5% workforce shrinkage, which could amount to 1,500 jobs for the company of 31,000-plus.

Those cuts will further Takeda's aim of saving $1 billion by 2017--money the company can use now that diabetes med Actos, once responsible for 18% of the company's worldwide sales, has lost patent protection. The company figures it can squeeze ¥25 billion ($240 million) from R&D by 2015, expanding that to ¥30 billion by 2017. It wants a similar amount trimmed from sales and marketing: ¥20 billion in cuts there in 2015, with another ¥5 billion by 2015.

To do that, the Japanese pharma plans to centralize administrative areas, like finance and IT, as well as its brand marketing organization to improve efficiency. As Roger told The Wall Street Journal in November, if the pace of layoffs tracks with that of overall cost savings, the job cuts will be front-loaded onto the next couple of years.

Takada already had a sizable wave of job cuts in its rearview mirror. In January 2012, the company announced 2,800 layoffs, as it integrated Swiss drugmaker Nycomed, a company it bought in 2011. Those cuts, mostly in Europe, ranged across the board in terms of operations; the company shed jobs in research, administration, operations and commercial functions. -- Carly Helfand (email | Twitter)

For more:
Special Reports: 10 Largest U.S. Patent Losses of 2012 - Actos | Top 10 Pharma Layoffs of 2012 - Takeda
Takeda's new outsider CFO charged with $1B cost-cutting plan
Takeda targets 2,800 jobs in Europe, U.S.
Takeda plots 1,400 job cuts at U.S. ops

Takeda - The top 10 largest pharma layoffs in 2013

Suggested Articles

Novartis is touting 52-week data for Cosentyx in spondyloarthritis––an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Gilead's remdesivir could bring in $7.6 billion in sales in 2022 and a decent profit margin, SVB Leerink predicted, but there are caveats.

Not wanting to be left behind in the COVID-19 vaccine race, Europe is stepping up its efforts secure supplies if any immunizations prove effective.